TitleAssociate Professor
InstitutionMD Anderson
DepartmentEndocrine Neoplasia & HD
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hamidi S, Hu MI. RET Kinase Inhibitors for the Treatment of RET-altered Thyroid Cancers: Current Knowledge and Future Directions. Ann Endocrinol (Paris). 2024 Feb 09. PMID: 38342224.
      Citations:    Fields:    
    2. Sarvestani AL, Lambdin J, Hu M, Cabanillas M, Waguespack SG, Hernandez JM, Zafereo ME. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Ann Surg Oncol. 2024 Jan 20. PMID: 38245643.
      Citations:    Fields:    
    3. Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins DR, Godbert Y, Ahn MJ, Cassier PA, Chul Cho B, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose M, Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40. PMID: 38009200.
      Citations:    Fields:    Translation:Humans
    4. Nardo M, Gouda MA, Nelson BE, Barreto CMN, Slade JH, Poullard A, Zafereo M, Hu MI, Cabanillas ME, Subbiah V. Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell Rep Med. 2023 12 19; 4(12):101332. PMID: 38118420; PMCID: PMC10772460.
      Citations:    Fields:    Translation:Humans
    5. Maniakas A, Sullivan A, Hu MI, Busaidy NL, Cabanillas ME, Dadu R, Waguespack SG, Fisher SB, Graham PH, Gross ND, Grubbs EG, Perrier ND, Wang JR, Gunn B, Garden AS, Megahed R, Navuluri S, Li X, Williams MD, Zafereo M. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer. Head Neck. 2024 Feb; 46(2):328-335. PMID: 38009416.
      Citations:    Fields:    Translation:Humans
    6. Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, F?hrer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ, LIBRETTO-531 Trial Investigators. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 Nov 16; 389(20):1851-1861. PMID: 37870969.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    7. Hamidi S, Hofmann MC, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne). 2023; 14:1176731. PMID: 37435488; PMCID: PMC10331470.
      Citations:    Fields:    Translation:Humans
    8. Nodit L, Hu MI, Alsharif O, Panella T. Letter to the Editor: ETV6-NTRK2 Fusion Identified in a Patient with Medullary Thyroid Carcinoma. Thyroid. 2023 06; 33(6):774-776. PMID: 36960705.
      Citations:    Fields:    Translation:Humans
    9. Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, Van Poznak C, Wu JY, Drake MT, El-Hajj Fuleihan G. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023 02 15; 108(3):507-528. PMID: 36545746.
      Citations: 1     Fields:    Translation:Humans
    10. Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, Waguespack SG, Wang JR, Maniakas A, Lai SY, Diersing J, Kwon M, Grubbs EG, Subbiah V, Williams MD, Zafereo ME. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid. 2023 01; 33(1):129-132. PMID: 36503246.
      Citations: 2     Fields:    Translation:Humans
    11. Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, Tahara M, Robinson B, Gao M, Xia M, Maeda P, Sherman E. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-na?ve RET-mutant medullary thyroid cancer. Future Oncol. 2022 Sep; 18(28):3143-3150. PMID: 35969032; PMCID: PMC10652291.
    12. Vodopivec DM, Hu MI. RET kinase inhibitors for RET-altered thyroid cancers. Ther Adv Med Oncol. 2022; 14:17588359221101691. PMID: 35756966; PMCID: PMC9218446.
    13. Hu MI. Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am. 2021 12; 50(4):721-728. PMID: 34774243.
      Citations:    Fields:    Translation:Humans
    14. Jaber T, Dadu R, Hu MI. Medullary thyroid carcinoma. Curr Opin Endocrinol Diabetes Obes. 2021 10 01; 28(5):540-546. PMID: 34292174.
      Citations:    Fields:    Translation:Humans
    15. Shojaie D, Hoffman AS, Amaku R, Cabanillas ME, Sosa JA, Waguespack SG, Zafereo ME, Hu MI, Grubbs EE. Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid. JMIR Form Res. 2021 Jul 16; 5(7):e27484. PMID: 34269691; PMCID: PMC8325074.
    16. Hu MI, Waguespack SG, Dosiou C, Ladenson PW, Livhits MJ, Wirth LJ, Sadow PM, Krane JF, Stack BC, Zafereo ME, Ali SZ, Weitzman SP, Hao Y, Babiarz JE, Kennedy GC, Kloos RT. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. J Clin Endocrinol Metab. 2021 07 13; 106(8):2198-2207. PMID: 34009369; PMCID: PMC8277199.
      Citations: 1     Fields:    Translation:Humans
    17. Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH, Godbert Y. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 08; 9(8):491-501. PMID: 34118198.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    18. Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer. 2021 06 02; 28(7):419-431. PMID: 33890870; PMCID: PMC8183642.
      Citations: 4     Fields:    Translation:Humans
    19. Jara MA, Varghese J, Hu MI. Adverse events associated with bone-directed therapies in patients with cancer. Bone. 2022 05; 158:115901. PMID: 33631354.
      Citations: 3     Fields:    Translation:Humans
    20. Van Poznak C, Reynolds EL, Estilo CL, Hu M, Schneider BP, Hertz DL, Gersch C, Thibert J, Thomas D, Banerjee M, Rae JM, Hayes DF. Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer. Oral Dis. 2022 Jan; 28(1):193-201. PMID: 33274559; PMCID: PMC8284838.
      Citations: 2     Fields:    Translation:Humans
    21. Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021 01; 43(1):E7-E12. PMID: 33169506; PMCID: PMC7756223.
      Citations: 7     Fields:    Translation:Humans
    22. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 10; 5(5):e000799. PMID: 33097651; PMCID: PMC7590373.
      Citations: 10     Translation:HumansCTClinical Trials
    23. Dadu R, Bagheri-Yarmand R, Ringel MD, Grubbs EG, Zafereo M, Cote G, Gagel RF, Robinson BG, Shaw KR, Hu MI. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs. Endocr Relat Cancer. 2020 08; 27(8):T27-T39. PMID: 32580150.
      Citations: 2     Fields:    Translation:Humans
    24. Krane JF, Cibas ES, Endo M, Marqusee E, Hu MI, Nasr CE, Waguespack SG, Wirth LJ, Kloos RT. The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decision-making from a fine-needle aspiration sample. Cancer Cytopathol. 2020 07; 128(7):452-459. PMID: 32543766; PMCID: PMC7384066.
      Citations: 7     Fields:    Translation:Humans
    25. Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328. PMID: 32437031; PMCID: PMC7262055.
      Citations: 11     Fields:    Translation:HumansCellsPHPublic Health
    26. Golant BT, Velez-Perez A, Krishnamurthy S, Guo M, Mousavi S, Hu MI, Varghese JM, Zafereo ME, Debnam JM. Thyroid carcinoma metastasizing to the submandibular gland: Sonographic findings. J Clin Ultrasound. 2020 May; 48(4):227-230. PMID: 32045024; PMCID: PMC7528955.
      Citations:    Fields:    Translation:Humans
    27. Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86. PMID: 31648931.
      Citations: 4     Fields:    Translation:Humans
    28. Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019 Aug; 145(8):1977-1986. PMID: 31309300.
      Citations: 6     Fields:    Translation:Humans
    29. Doan HQ, Hu MI, Goldstein J, Piha-Paul SA, Subbiah V, Patel AB. Vandetanib photoinduced cutaneous toxicities. Cutis. 2019 May; 103(5):E24-E29. PMID: 31233590.
      Citations: 1     Fields:    Translation:Humans
    30. Hu MI, Elisei R, Dedecjus M, Popovtzer A, Druce M, Kapiteijn E, Pacini F, Locati L, Krajewska J, Weiss R, Gagel RF. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocr Relat Cancer. 2019 02 01; 26(2):241-250. PMID: 30557850.
      Citations: 7     Fields:    Translation:Humans
    31. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472. PMID: 30383888; PMCID: PMC6340722.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    32. Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid. 2018 10; 28(10):1243-1251. PMID: 30132401; PMCID: PMC6157359.
      Citations: 41     Fields:    Translation:Humans
    33. Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and cancer: Differential diagnosis and treatment. CA Cancer J Clin. 2018 09; 68(5):377-386. PMID: 30240520.
      Citations: 23     Fields:    Translation:Humans
    34. Vodopivec DM, Silva AM, Garcia-Banigan DC, Christakis I, Stewart A, Schwarz K, Hussey CS, Bassett R, Hu MI, Perrier ND. Gender differences in bone mineral density in patients with sporadic primary hyperparathyroidism. Endocrinol Diabetes Metab. 2018 Oct; 1(4):e00037. PMID: 30815565; PMCID: PMC6354761.
      Citations: 5     Fields:    
    35. Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 07; 8(7):836-849. PMID: 29657135.
      Citations: 109     Fields:    Translation:HumansAnimalsCells
    36. Romero Arenas MA, Rich TA, Hyde SM, Busaidy NL, Cote GJ, Hu MI, Gagel RF, Gidley PW, Jimenez C, Kupferman ME, Peterson SK, Sherman SI, Ying A, Bassett RL, Waguespack SG, Perrier ND, Grubbs EG. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402. PMID: 29427212; PMCID: PMC10013431.
      Citations: 6     Fields:    Translation:Humans
    37. Pena I, Clayman GL, Grubbs EG, Bergeron JM, Waguespack SG, Cabanillas ME, Dadu R, Hu MI, Fellman BM, Li Y, Gross ND, Lai SY, Sturgis EM, Zafereo ME. Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head Neck. 2018 Jan; 40(1):79-85. PMID: 29044788.
      Citations: 4     Fields:    Translation:Humans
    38. Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017 09 01; 102(9):3591-3599. PMID: 28911154; PMCID: PMC5587058.
      Citations: 22     Fields:    Translation:Humans
    39. Long KL, Etzel C, Rich T, Hyde S, Perrier ND, Graham PH, Lee JE, Hu MI, Cote GJ, Gagel R, Grubbs EG. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. Fam Cancer. 2017 04; 16(2):283-289. PMID: 27864651.
      Citations: 4     Fields:    Translation:Humans
    40. Xu JY, Grubbs EG, Waguespack SG, Jimenez C, Gagel RF, Sosa JA, Sellin RV, Dadu R, Hu MI, Trotter CS, Jackson M, Rich TA, Hyde SM, Sherman SI, Cote GJ. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 2016 12; 26(12):1744-1751. PMID: 27673361; PMCID: PMC5175438.
      Citations:    Fields:    Translation:Humans
    41. Xu JY, Murphy WA, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI, Milton DR. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877. PMID: 27662441; PMCID: PMC5155685.
      Citations: 7     Fields:    Translation:Humans
    42. Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4461-4467. PMID: 27575943; PMCID: PMC5095245.
      Citations: 11     Fields:    Translation:HumansCells
    43. Edwards BJ, Sun M, West DP, Guindani M, Lin YH, Lu H, Hu M, Barcenas C, Bird J, Feng C, Saraykar S, Tripathy D, Hortobagyi GN, Gagel R, Murphy WA. Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. J Bone Miner Res. 2016 08; 31(8):1569-76. PMID: 26896384.
      Citations: 10     Fields:    Translation:Humans
    44. Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol. 2016 05 20; 34(15):1741-7. PMID: 27001565; PMCID: PMC4966337.
      Citations: 28     Fields:    Translation:Humans
    45. Cabanillas ME, Dadu R, Hu MI, Lu C, Gunn GB, Grubbs EG, Lai SY, Williams MD. Thyroid Gland Malignancies. Hematol Oncol Clin North Am. 2015 Dec; 29(6):1123-43. PMID: 26568552.
      Citations: 6     Fields:    Translation:Humans
    46. Thosani S, Hu MI. Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol. 2015; 11(21):2865-71. PMID: 26403973; PMCID: PMC4976858.
      Citations: 16     Fields:    Translation:Humans
    47. Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid. 2015 Oct; 25(10):1085-90. PMID: 26200040; PMCID: PMC4589264.
      Citations: 10     Fields:    Translation:Humans
    48. Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine. 2016 Feb; 51(2):351-9. PMID: 26206754.
      Citations: 8     Fields:    Translation:Humans
    49. Hu M. Response letter to the editor. J Clin Endocrinol Metab. 2015 Jan; 100(1):L7. PMID: 25559546.
      Citations:    Fields:    Translation:Humans
    50. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81. PMID: 25353071; PMCID: PMC4283003.
      Citations: 48     Fields:    Translation:Humans
    51. Cabanillas ME, Hu MI, Jimenez C. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions. J Clin Endocrinol Metab. 2014 Dec; 99(12):4390-6. PMID: 25238206; PMCID: PMC4255127.
      Citations: 16     Fields:    Translation:Humans
    52. Talpur R, Cox KM, Hu M, Geddes ER, Parker MK, Yang BY, Armstrong PA, Liu P, Duvic M. Vitamin D deficiency in mycosis fungoides and S?zary syndrome patients is similar to other cancer patients. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):518-24. PMID: 25442486.
      Citations: 9     Fields:    Translation:Humans
    53. Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK, Hu MI. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014 Sep; 99(9):3144-52. PMID: 24915117; PMCID: PMC4154084.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    54. Glezerman IG, Hu MI, Jain RK. Response. J Natl Cancer Inst. 2014 Jul; 106(7). PMID: 24906399.
      Citations:    Fields:    Translation:Humans
    55. Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying A, Grubbs E. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106. PMID: 24617864; PMCID: PMC4080849.
      Citations: 13     Fields:    Translation:Humans
    56. Hu MI, Ying AK, Jimenez C. Update on medullary thyroid cancer. Endocrinol Metab Clin North Am. 2014 Jun; 43(2):423-42. PMID: 24891170.
      Citations: 14     Fields:    Translation:Humans
    57. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82. PMID: 24733667; PMCID: PMC4012968.
      Citations: 12     Fields:    Translation:Humans
    58. Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B, Cabanillas ME. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 2014 May; 24(5):918-22. PMID: 24635127; PMCID: PMC4026371.
      Citations: 39     Fields:    Translation:Humans
    59. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94. PMID: 24628550; PMCID: PMC4037722.
      Citations: 35     Fields:    Translation:Humans
    60. Cabanillas ME, Hu MI, Jimenez C, Grubbs EG, Cote GJ. Treating medullary thyroid cancer in the age of targeted therapy. Int J Endocr Oncol. 2014; 1(2):203-216. PMID: 25908961; PMCID: PMC4405124.
      Citations: 6     
    61. Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, Cote G, Waguespack SG, Habra MA, Jimenez C. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013 Nov; 98(11):E1813-9. PMID: 24030942; PMCID: PMC5399523.
      Citations: 26     Fields:    Translation:Humans
    62. Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2013 Sep 18; 105(18):1417-20. PMID: 23990665; PMCID: PMC3776443.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    63. Chae YK, Hu MI, Katz RL, Chavez-MacGregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol. 2013 Aug 10; 31(23):e398-400. PMID: 23796991; PMCID: PMC4878051.
      Citations: 2     Fields:    Translation:Humans
    64. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42. PMID: 23185034; PMCID: PMC3537108.
      Citations: 30     Fields:    Translation:Humans
    65. Rianon N, Alex G, Callender G, Jimenez C, Hu M, Grubbs E, Moreno M, Wathoo C, Petak S, Perrier N. Preoperative serum osteocalcin may predict postoperative elevated parathyroid hormone in patients with primary hyperparathyroidism. World J Surg. 2012 Jun; 36(6):1320-6. PMID: 22278606.
      Citations: 3     Fields:    Translation:Humans
    66. Hu MI, Cote GJ. Medullary thyroid carcinoma: who's on first? Thyroid. 2012 May; 22(5):451-3. PMID: 22545752.
      Citations: 5     Fields:    Translation:Humans
    67. Landry CS, Grubbs EG, Hernandez M, Hu MI, Hansen MO, Lee JE, Perrier ND. Predictable criteria for selective, rather than routine, calcium supplementation following thyroidectomy. Arch Surg. 2012 Apr; 147(4):338-44. PMID: 22184134; PMCID: PMC4809199.
      Citations: 18     Fields:    Translation:Humans
    68. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res. 2011; 2011:985780. PMID: 22007339; PMCID: PMC3189619.
      Citations: 28     
    69. Hu MI. Updates in the management of medullary thyroid cancer. Clin Adv Hematol Oncol. 2011 May; 9(5):391-4. PMID: 21685868.
      Citations: 2     Fields:    Translation:Humans
    70. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011 Oct 01; 117(19):4381-9. PMID: 21412758; PMCID: PMC3134535.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    71. Khan MI, Waguespack SG, Hu MI. Medical management of postsurgical hypoparathyroidism. Endocr Pract. 2011 Mar-Apr; 17 Suppl 1:18-25. PMID: 21134871.
      Citations: 25     Fields:    Translation:Humans
    72. Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Hu MI, Cote G, Habra MA. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid. 2011 Feb; 21(2):189-92. PMID: 21186952; PMCID: PMC3025175.
      Citations: 21     Fields:    Translation:Humans
    73. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2011 Feb; 1218:47-54. PMID: 20946574.
      Citations: 28     Fields:    Translation:Humans
    74. Hu MI, Lu H, Gagel RF. Cancer therapies and bone health. Curr Rheumatol Rep. 2010 Jun; 12(3):177-85. PMID: 20437119.
      Citations: 4     Fields:    Translation:Humans
    75. Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R. Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv. 2009 Jun; 3(2):75-88. PMID: 19412668.
      Citations: 20     Fields:    Translation:Humans
    76. Hoff AO, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN, Toth BB. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008 Jun; 23(6):826-36. PMID: 18558816; PMCID: PMC2677083.
      Citations: 166     Fields:    Translation:Humans
    77. Hu MI, Gagel RF, Jim?nez C. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am. 2008 Jun; 37(2):481-96, x-xi. PMID: 18502338.
      Citations: 27     Fields:    Translation:Humans
    78. Grubbs EG, Rich TA, Li G, Sturgis EM, Younes MN, Myers JN, Edeiken-Monroe B, Fornage BD, Monroe DP, Staerkel GA, Williams MD, Waguespack SG, Hu MI, Cote G, Gagel RF, Cohen J, Weber RS, Anaya DA, Holsinger FC, Perrier ND, Clayman GL, Evans DB. Recent advances in thyroid cancer. In brief. Curr Probl Surg. 2008 Mar; 45(3):149-51. PMID: 18346476.
      Citations: 1     Fields:    Translation:Humans
    79. Grubbs EG, Rich TA, Li G, Sturgis EM, Younes MN, Myers JN, Edeiken-Monroe B, Fornage BD, Monroe DP, Staerkel GA, Williams MD, Waguespack SG, Hu MI, Cote G, Gagel RF, Cohen J, Weber RS, Anaya DA, Holsinger FC, Perrier ND, Clayman GL, Evans DB. Recent advances in thyroid cancer. Curr Probl Surg. 2008 Mar; 45(3):156-250. PMID: 18346477.
      Citations: 19     Fields:    Translation:Humans
    80. Hu MI, Gagel RF, Jimenez C. Bone loss in patients with breast or prostate cancer. Curr Osteoporos Rep. 2007 Dec; 5(4):170-8. PMID: 18430392.
      Citations: 6     Fields:    Translation:Humans
    81. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 2001 Jul 15; 61(14):5652-9. PMID: 11454720.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    82. Calcitonin Gene Family of Peptides. 813-836.
    83. Association of Vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein. Journal of Clinical Oncology. 34:1741-1747.
    84. Endocrinologic issues. 343-360.
    85. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. Familial Cancer. 1-7.
    86. Bone metastases and skeletal-related events in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 101:4871-4877.
    87. Endocrine Complications of Head and Neck Surgery. 85-103.
    88. Detection and prognostic significance of circulating tumor cells in patients with metastatic thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 101:4461-4467.
    89. Efficacy of the natural clay, calcium aluminosilicate anti-diarrheal, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life. Thyroid. 25:1085-1090.
    90. Denosumab. Future Oncology. 11:2865-2871.
    91. Preexisting adrenal masses in patients with adrenocortical carcinoma. Endocrine.
    92. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 26:1744-1751.
    93. Efficacy and tolerability of vemurafenib in patients with BRAFV600E positive papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 100:E77-E81.
    HU's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (304)
    Co-Authors (93)
    Similar People (60)
    Same Department Expand Description